Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study
Mirikizumab 治疗溃疡性结肠炎 152 周连续治疗三年后的疗效和安全性:LUCENT-3 开放标签扩展研究的结果
期刊:Inflammatory Bowel Diseases
影响因子:4.3
doi:10.1093/ibd/izae253
Sands, Bruce E; D'Haens, Geert; Clemow, David B; Irving, Peter M; Johns, Jordan T; Gibble, Theresa Hunter; Abreu, Maria T; Lee, Scott D; Hisamatsu, Tadakazu; Kobayashi, Taku; Dubinsky, Marla C; Vermeire, Severine; Siegel, Corey A; Peyrin-Biroulet, Laurent; Moses, Richard E; Milata, Joe; Panaccione, Remo; Dignass, Axel